Treatment-Emergent Adverse Event (TEAE)
A treatment-emergent adverse event is any adverse event that first appears or worsens after the first dose of study drug, regardless of whether the drug is believed to have caused it.
The term defines a counting convention rather than a clinical judgement. An event counts as treatment-emergent if it began after the first dose, or was present beforehand and became worse in frequency or severity afterwards. Causality is recorded in a separate field and does not affect whether the event enters the table. Events are mapped to a standard dictionary of preferred terms so that a dozen investigator phrasings collapse into one countable row.
This is why the placebo column is the whole point of a safety table. In the 68-week semaglutide obesity trial, nausea was reported by roughly forty-four percent of participants on active drug and by around eighteen percent on placebo, and discontinuation for adverse events ran at a few percent in each arm with the active group higher. The between-arm difference, not the headline percentage, is the attributable estimate.
Exposure is the second correction. Trials with unequal follow-up accumulate events mechanically in whichever arm stays on treatment longer, so rates are often re-expressed per hundred patient-years. Open-label extensions inflate raw counts for exactly this reason, and comparing a two-year extension figure with a one-year randomised figure produces an apparent worsening that is entirely an artefact of time.
In marketing copy the convention is inverted. A treatment-emergent percentage gets quoted as a rate of harm caused by the drug, when a label lists events that crossed a reporting threshold and exceeded placebo, and inclusion is not proof of causation for any individual case. The mirror error is treating a low number from a small early-phase study as reassurance, when the sample could never have detected an uncommon event.